Anouk Boudewijn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anouk Boudewijn has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Dianne B.P.M. Somhorst
Wageningen Food & Biobased Research, Wageningen University & Research, Bornse Weilanden 9, Wageningen, 6708 WG, The Netherlands
2 shared publications - Govardus A.H. de Jong
Wageningen Food & Biobased Research, Wageningen University & Research, Bornse Weilanden 9, Wageningen, 6708 WG, The Netherlands
2 shared publications - Shanna Bastiaan-Net
Wageningen Food and Biobased Research, Wageningen University and Research, Wageningen, The Netherlands
2 shared publications - Aimane Mechroubi
Department of Cardiology, UMC Utrecht , Utrecht
1 shared publication - Alinda J. Berends
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
1 shared publication - Angela H. E. M. Maas
Cardiology for Women, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Patients with angina and non-obstructive coronary artery disease undergoing comprehensive invasive coronary function testing: long-term clinical outcomes
Background and Aims: Comprehensive evaluation by invasive coronary function test (CFT) of patients with angina and non-obstructive coronary artery disease is recommended in the current guidelines. The prognosis of patients with CFT-proven coronary vasomotor dysfunction (CVDys) is less well-known. Methods: Patients that provided consent for the previously published NL-CFT registry who underwent clinically indicated invasive CFT between 1 February 2019 and 1 June 2024 were included. Patients with CVDys, defined as an abnormal spasm provocation test and/or microvascular functional assessment, were compared to patients with normal CFT. The primary outcome of major adverse cardiovascular events and emergency room visits for angina (MACE-EA) was defined as a composite of all-cause death, acute coronary syndrome, stroke/transient ischaemic attack, revascularization, repeat angiography without intervention, heart failure hospitalizations, and unplanned hospitalizations or emergency room visits due to angina. Results: In total, 1355 patients were included. In 79.8%, CFT was abnormal, and vasospasm was the most prevalent endotype. In 1252 patients, follow-up of clinical events was complete. During a mean follow-up of 33 ± 13 months, CVDys patients had almost double the number of primary outcome events compared with patients with a normal CFT (31.2% vs 16.8%, P < .001), driven by emergency care visits for angina. Secondary clinical endpoints including death, myocardial infarction, stroke, or revascularization were low and comparable between the groups. Conclusions: The long-term risk of MACE-EA is doubled in ANOCA patients with CFT-confirmed CVDys compared with normal CFT results. Events are dominated by emergency room visits due to angina, illustrating the high disease burden of CVDys. Their (angina-related) health status is significantly worse at follow-up.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessPatients with angina and non-obstructive coronary artery disease undergoing comprehensive invasive coronary function testing: long-term clinical outcomes
Background and Aims: Comprehensive evaluation by invasive coronary function test (CFT) of patients with angina and non-obstructive coronary artery disease is recommended in the current guidelines. The prognosis of patients with CFT-proven coronary vasomotor dysfunction (CVDys) is less well-known. Methods: Patients that provided consent for the previously published NL-CFT registry who underwent clinically indicated invasive CFT between 1 February 2019 and 1 June 2024 were included. Patients with CVDys, defined as an abnormal spasm provocation test and/or microvascular functional assessment, were compared to patients with normal CFT. The primary outcome of major adverse cardiovascular events and emergency room visits for angina (MACE-EA) was defined as a composite of all-cause death, acute coronary syndrome, stroke/transient ischaemic attack, revascularization, repeat angiography without intervention, heart failure hospitalizations, and unplanned hospitalizations or emergency room visits due to angina. Results: In total, 1355 patients were included. In 79.8%, CFT was abnormal, and vasospasm was the most prevalent endotype. In 1252 patients, follow-up of clinical events was complete. During a mean follow-up of 33 ± 13 months, CVDys patients had almost double the number of primary outcome events compared with patients with a normal CFT (31.2% vs 16.8%, P < .001), driven by emergency care visits for angina. Secondary clinical endpoints including death, myocardial infarction, stroke, or revascularization were low and comparable between the groups. Conclusions: The long-term risk of MACE-EA is doubled in ANOCA patients with CFT-confirmed CVDys compared with normal CFT results. Events are dominated by emergency room visits due to angina, illustrating the high disease burden of CVDys. Their (angina-related) health status is significantly worse at follow-up.
- Open Access
- 27 June 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 13, 101488
In vitro protein digestibility and colonic fermentation of mycoprotein-based meat analogues
- 27 June 2026
- Published by Elsevier in Current Research in Food Science
- Vol. 13, 101488
Open AccessIn vitro protein digestibility and colonic fermentation of mycoprotein-based meat analogues
- Open Access
Ex vivo autologous immune cell assay to study modulation of type 2 Inflammation by processed- or novel food extracts in peanut allergy
Peanut allergy represents a major food-allergy burden, raising concerns about food processing and novel dietary products. Current diagnostics assess primarily allergic endpoints rather than immune mechanisms initiating and maintaining type 2 inflammation, particularly DC2-mediated Th2 polarization. Here, an ex vivo autologous type 2 inflammatory monocyte-derived dendritic cell (moDC) DC2/T cell and B cell assay has been introduced enabling to study immunomodulatory effects induced by unprocessed (P-D) versus processed (P-DH (heated) or P-DHG (heated and glycated)) peanut proteins. Separately, different emerging food samples were assessed (protein concentrates or whole biomass) enabling to study their capacities to modify inflammatory DC2/T cell responses. CD14⁺ monocytes, CD4 + T cells and CD19⁺ B cells were isolated from six peanut-allergic patients’ PBMCs. MoDCs generated with IL4/GM-CSF were exposed (48h) to type 2 polarizing cytokine (DC2) mix, or DC2 mix combined with the food samples. Next, DC2s were co-cultured with T cells (5d), followed by B cells incubation with DC2/T cell supernatant and food samples (10d). Supernatants and cells were analyzed for Th1/Th2/Th-regulatory (Treg) cells, IgE and IgG profiles. DC2 induced a strong Th2 phenotype and activity, P-D DC2 further enhanced IL13 secretion and %Tregs. P-DH DC2 favored Th2, whereas P-DHG DC2 increased IFNγ, with neither increasing %Treg. P-D and P-DH DC2 increased CD40L + CD25 + memory Th2, and P-DHG showed the same tendency. Wheat, whey and seaweed biomass had little effect on DC2/Th2 driven type 2 inflammation at the dose studied, whereas algae showed distinct immunomodulatory, adjuvant-like activity upon co-exposure during inflammatory DC2 maturation. In conclusion, this autologous in vitro assay captures modification of type 2 inflammatory response in DC2-Th2 interaction, which can compile both allergen-specific and generic reactivity to food samples, supporting the potential future use of this assay as an additional tool to assess type 2-driving potential and possible allergenicity of emerging foods and processing methods in peanut-allergic patients. Graphical Immune cell and other illustration elements were adapted from (1, 2) and (54). Illustrations from (1, 2) were adapted with permission; permission conveyed through Copyright Clearance Center, Inc. Reference (1): © The Authors, published by Wiley-VCH GmbH under a CC BY-NC-ND license. Reference (2): © The Authors, published by Elsevier Ltd under a CC BY 4.0 license. Illustrations from (54) were adapted under the terms of the CC BY 4.0 license; © The Authors, published by Wiley-VCH GmbH. Capsule summary: The autologous moDC-T cell-B cell in vitro assay may be used to assess whether processing methods or new foods might have intrinsic capacity to affect type 2 inflammation in peanut-allergic patients.
Open AccessEx vivo autologous immune cell assay to study modulation of type 2 Inflammation by processed- or novel food extracts in peanut allergy
Peanut allergy represents a major food-allergy burden, raising concerns about food processing and novel dietary products. Current diagnostics assess primarily allergic endpoints rather than immune mechanisms initiating and maintaining type 2 inflammation, particularly DC2-mediated Th2 polarization. Here, an ex vivo autologous type 2 inflammatory monocyte-derived dendritic cell (moDC) DC2/T cell and B cell assay has been introduced enabling to study immunomodulatory effects induced by unprocessed (P-D) versus processed (P-DH (heated) or P-DHG (heated and glycated)) peanut proteins. Separately, different emerging food samples were assessed (protein concentrates or whole biomass) enabling to study their capacities to modify inflammatory DC2/T cell responses. CD14⁺ monocytes, CD4 + T cells and CD19⁺ B cells were isolated from six peanut-allergic patients’ PBMCs. MoDCs generated with IL4/GM-CSF were exposed (48h) to type 2 polarizing cytokine (DC2) mix, or DC2 mix combined with the food samples. Next, DC2s were co-cultured with T cells (5d), followed by B cells incubation with DC2/T cell supernatant and food samples (10d). Supernatants and cells were analyzed for Th1/Th2/Th-regulatory (Treg) cells, IgE and IgG profiles. DC2 induced a strong Th2 phenotype and activity, P-D DC2 further enhanced IL13 secretion and %Tregs. P-DH DC2 favored Th2, whereas P-DHG DC2 increased IFNγ, with neither increasing %Treg. P-D and P-DH DC2 increased CD40L + CD25 + memory Th2, and P-DHG showed the same tendency. Wheat, whey and seaweed biomass had little effect on DC2/Th2 driven type 2 inflammation at the dose studied, whereas algae showed distinct immunomodulatory, adjuvant-like activity upon co-exposure during inflammatory DC2 maturation. In conclusion, this autologous in vitro assay captures modification of type 2 inflammatory response in DC2-Th2 interaction, which can compile both allergen-specific and generic reactivity to food samples, supporting the potential future use of this assay as an additional tool to assess type 2-driving potential and possible allergenicity of emerging foods and processing methods in peanut-allergic patients. Graphical Immune cell and other illustration elements were adapted from (1, 2) and (54). Illustrations from (1, 2) were adapted with permission; permission conveyed through Copyright Clearance Center, Inc. Reference (1): © The Authors, published by Wiley-VCH GmbH under a CC BY-NC-ND license. Reference (2): © The Authors, published by Elsevier Ltd under a CC BY 4.0 license. Illustrations from (54) were adapted under the terms of the CC BY 4.0 license; © The Authors, published by Wiley-VCH GmbH. Capsule summary: The autologous moDC-T cell-B cell in vitro assay may be used to assess whether processing methods or new foods might have intrinsic capacity to affect type 2 inflammation in peanut-allergic patients.